New vaccine could help throat cancer patients avoid radiation

NCT ID NCT06223568

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 2 trial tests whether adding an experimental vaccine (PRGN-2009) to standard chemotherapy can improve outcomes for people with newly diagnosed HPV-related throat cancer, potentially allowing them to skip radiation. About 70 adults will receive either chemo alone or chemo plus the vaccine, followed by surgery. The goal is to see if the combination leads to a complete response in the tumor.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
PRGN-2009 vaccine combined with docetaxel and cisplatin chemotherapy
What this could lead to
If successful, this could offer a way to treat HPV-related throat cancer without radiation, reducing side effects while maintaining survival rates.
What could go wrong
This is a small, early-phase trial (70 people) testing a new vaccine. It may not work better than standard treatment, and side effects from the vaccine or chemo are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER VACCINE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • National Institutes of Health Clinical Center

    RECRUITING

    Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.